HLI
Status-Quo-PlayerHaleon
$356.00
-0.73%
Delayed
Power Core
The power core of Haleon is healthcare professional endorsement compounded into consumer default purchasing behavior, ring-fenced by therapeutic claim barriers that regulators take decades to approve.
Direction of Movement
lateral
ROC 200
-4.6%
Direction Signals
- Revenue trajectory: GBP 10.86 billion (2022), GBP 11.30 billion (2023), GBP 11.23 billion (2024), GBP 11.03 billion (2025). Four consecutive years of essentially flat top line, with a slight contraction in the most recent period.
- Analyst consensus projects GBP 11.40 billion in 2026, GBP 11.90 billion in 2027, GBP 12.43 billion in 2028, reaching GBP 13.42 billion by 2030. This is approximately 4% CAGR, which matches the natural growth pace of consumer healthcare categories rather than indicating share gains.
- Operating margin has expanded from 17.2% in 2022 to 22.4% in 2025. This demonstrates pricing power and portfolio discipline but is finite: margins cannot compound indefinitely, and the easy gains from portfolio simplification have largely been taken.
- Net debt has declined from GBP 9.76 billion at spin-off to GBP 7.29 billion at end-2025, a reduction of roughly GBP 2.5 billion. The 2025 cash flow statement shows GBP 1.31 billion in net debt repayment.
Haleon plc entered public markets in July 2022 as the largest consumer healthcare pure-play ever spun out, carrying a portfolio of brands that most people have touched without knowing they shared a parent: Sensodyne toothpaste, Panadol paracetamol, Voltaren topical pain gel, Advil ibuprofen (in select markets), Centrum multivitamins, Otrivin nasal sprays, and the denture care franchise of Polident and Poligrip. These names were assembled over a century through the combined consumer health operations of GlaxoSmithKline and Pfizer, with Novartis assets layered in. The spin-off was positioned as a liberation event: a business that had been subsidizing pharmaceutical R&D pipelines inside larger conglomerates would finally be allowed to run as a focused category operator.
Four years into public life, the numbers tell a specific story. Revenue has stalled in a narrow band between GBP 11.0 billion and GBP 11.3 billion across 2023, 2024, and 2025. EBIT margin has climbed from 17.2% in the spin-off year to 22.4% in FY2025. Net debt has fallen from GBP 9.76 billion to GBP 7.29 billion. Earnings per share has moved from GBP 0.11 to GBP 0.19. The company is deleveraging, buying back shares (GBP 654 million in 2025), and converting operating income into free cash flow at a rate (GBP 2.02 billion FCF on GBP 2.48 billion EBIT) that most consumer staples peers would envy.
The central analytical question is not whether Haleon is a good business. It plainly is. The question is what kind of power it actually wields. Consumer healthcare sits in an unusual strategic zone: it looks like consumer staples from the shelf but behaves like pharma from the purchase decision. The L17X observation is this: Haleon's moat is not its brands. Its moat is the pharmacist, the dentist, and the general practitioner who recommend those brands by name, and that endorsement layer cannot be bought with advertising. Understanding that distinction determines whether the flat revenue trajectory is a symptom of weakness or a feature of a structurally dominant business operating at category-growth pace.
This analysis continues with 6 more sections.
Continue reading: Role Assignment · Strategic Environment · Dependency Matrix · Self-Image & Mission · Direction of Movement · Portfolio Lens
Read full analysis — freeCreate a free account. No credit card. No trial period.